Search

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Read more

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Read more

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Read more

Policy on life events

EHA has a policy on life events and eligibility. If you're submitting a grant application and the policy applies to your circumstances, you can ask us to extend the period of eligibility.

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more

Borderless careers

Start enriching your professional journey with EHA todayAdvance your career at any stage with the European Hematology Association.

Read more

Faculty Information

We are honored that you have agreed to be part of the faculty for the EHA-SfPM Precision Medicine Meeting, to be held on September 25-27, 2024 in Copenhagen, Denmark

On this page, you will find the important deadlines as well as…

Read more

Publications

During 2023 and 2024, the SWG on Pediatric Hematology contributed to the development of the EHA SIOPe Pediatric Extended Syllabus. This syllabus will be the basis for our future activities in the educational space.

Read more

Sponsor opportunities

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies with the practical tools to translate emerging data into the best therapy for…

Read more